CyberKnife Radiosurgery for Locally Recurrent Prostate CA

Status Recruiting

Clinical Trial Summary

The purpose of this study is to scientifically evaluate the effects (good and bad) of a new type of radiation treatment in patients with locally recurrent prostate cancer after prior radiotherapy. The treatment is known as prostate radiosurgery, and is distinguished from traditional radiotherapy by the application of smaller, more precisely controlled margins around the area targeted for full dose radiation, and far fewer treatments, using a much larger dose per treatment.

This research is being done to see what advantages, if any, prostate radiosurgery may have over other salvage treatment methods, including brachytherapy, cryosurgery, high intensity focused ultrasound (HIFU), hormonal therapy and radical prostatectomy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Recurrent Prostate Cancer

Clinical Trial Details

NCT number	NCT00851916
Study type	Interventional
Source	CyberKnife Centers of San Diego
Contact	Carlyn Tripp
Phone	619-230-0400
Email	ctripp@rmgmed.com
Status	Recruiting
Phase	Phase 2
Start date	February 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02217709` - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer	Phase 2
Recruiting	`NCT03718260` - PSMA-PET Registry for Recurrent Prostate Cancer	N/A
Active, not recruiting	`NCT01685125` - Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 2
Completed	`NCT01054079` - Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer	Phase 2
Terminated	`NCT00512668` - Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer	Phase 1
Completed	`NCT00103194` - Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer	Phase 2
Completed	`NCT00087139` - Ixabepilone in Treating Patients With Metastatic Prostate Cancer	Phase 2
Recruiting	`NCT05304858` - Tumor Microenvironment Analysis of Prostate Cancer Metastasis
Completed	`NCT02250014` - The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer	Phase 1
Active, not recruiting	`NCT01655836` - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer	Phase 1
Terminated	`NCT01866423` - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 2
Not yet recruiting	`NCT06070272` - Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Completed	`NCT01468532` - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 1/Phase 2
Completed	`NCT01260688` - Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel	Phase 2
Completed	`NCT01682941` - Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen	N/A
Completed	`NCT01220817` - Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study	Phase 2
Completed	`NCT00775866` - MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy	N/A
Completed	`NCT00074022` - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05044754` - SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy
Active, not recruiting	`NCT01923506` - Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery	Phase 1